CompletedPhase 2NCT04200755
Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma
Studying Localized scleroderma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Cologne
- Principal Investigator
- Sabine Eming, Prof. Dr.University of Cologne
- Intervention
- Dupilumab 300Mg Solution for Injection(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (4)
- Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany
- Uniklinik Köln, Klinik für Dermatologie und Venerologie, Cologne, Germany
- Helios St. Elisabeth Klinik Oberhausen, Klinik für Dermatologie, Venerologie und Allergologie, Oberhausen, Germany
- Universitäts-Hautklinik Tübingen, Tübingen, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04200755 on ClinicalTrials.gov